NASDAQ:AMYT

Amryt Pharma News Headlines

$13.72
-0.13 (-0.94 %)
(As of 04/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$13.70
Now: $13.72
$13.99
50-Day Range
$13.03
MA: $14.06
$14.74
52-Week Range
$10.06
Now: $13.72
$15.50
Volume11,316 shs
Average Volume20,988 shs
Market Capitalization$492.23 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Amryt Pharma (NASDAQ AMYT) News Headlines Today

SourceHeadline
Amryt Pharma (NASDAQ:AMYT) Sees Strong Trading VolumeAmryt Pharma (NASDAQ:AMYT) Sees Strong Trading Volume
americanbankingnews.com - April 8 at 11:30 AM
Amryt Pharma hopeful of winning fast-track US approval for breakthrough skin gelAmryt Pharma hopeful of winning fast-track US approval for breakthrough skin gel
proactiveinvestors.com - March 31 at 8:51 AM
Maxim Group Initiates Coverage on Amryt Pharma (NASDAQ:AMYT)Maxim Group Initiates Coverage on Amryt Pharma (NASDAQ:AMYT)
americanbankingnews.com - March 31 at 8:36 AM
Amryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)Amryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
finance.yahoo.com - March 31 at 3:50 AM
Amryt Pharma encouraged by study of lomitapide in Familial Chylomicronaemia SyndromeAmryt Pharma encouraged by study of lomitapide in Familial Chylomicronaemia Syndrome
proactiveinvestors.com - March 30 at 7:48 AM
Short Interest in Amryt Pharma plc (NASDAQ:AMYT) Rises By 77.6%Short Interest in Amryt Pharma plc (NASDAQ:AMYT) Rises By 77.6%
americanbankingnews.com - March 30 at 1:18 AM
Minerva Neurosciences (NASDAQ:NERV) & Amryt Pharma (NASDAQ:AMYT) Financial SurveyMinerva Neurosciences (NASDAQ:NERV) & Amryt Pharma (NASDAQ:AMYT) Financial Survey
americanbankingnews.com - March 26 at 8:36 PM
Amryt Pharma (NASDAQ:AMYT) Sees Large Volume IncreaseAmryt Pharma (NASDAQ:AMYT) Sees Large Volume Increase
americanbankingnews.com - March 23 at 11:40 AM
Amryt Pharma plc (AMYT)Amryt Pharma plc (AMYT)
in.finance.yahoo.com - March 17 at 7:24 AM
Amryt Pharma inks Canada distribution agreement for Myalepta drugAmryt Pharma inks Canada distribution agreement for Myalepta drug
proactiveinvestors.com - March 8 at 7:46 AM
Amryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in CanadaAmryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada
finance.yahoo.com - March 8 at 7:46 AM
Amryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi ArabiaAmryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia
finance.yahoo.com - December 17 at 7:57 AM
Amryt Pharma gets marketing approval in Brazil for specialist cholesterol drug LojuxtaAmryt Pharma gets marketing approval in Brazil for specialist cholesterol drug Lojuxta
proactiveinvestors.com - December 9 at 7:39 AM
Amryt Group Receives Marketing Authorisation Approval for Lojuxta® in BrazilAmryt Group Receives Marketing Authorisation Approval for Lojuxta® in Brazil
finance.yahoo.com - December 9 at 2:18 AM
Amryt Pharma ups forecasts as sales accelerate in third quarterAmryt Pharma ups forecasts as sales accelerate in third quarter
proactiveinvestors.com - November 5 at 5:35 PM
Amryt Reports Record Q3 2020 Results - Raising FY 2020 Revenue GuidanceAmryt Reports Record Q3 2020 Results - Raising FY 2020 Revenue Guidance
finance.yahoo.com - November 5 at 7:33 AM
AMRYT ANNOUNCES POSITIVE RESULTS FROM PHASE 3 TRIAL OF FILSUVEZ® IN EPIDERMOLYSIS BULLOSAAMRYT ANNOUNCES POSITIVE RESULTS FROM PHASE 3 TRIAL OF FILSUVEZ® IN EPIDERMOLYSIS BULLOSA
finance.yahoo.com - October 29 at 7:24 AM
MIDAS SHARE TIPS UPDATE: Amryt drug may be winnerMIDAS SHARE TIPS UPDATE: Amryt drug may be winner
msn.com - October 16 at 4:47 PM
Exercise of Warrants & Issue of Ordinary Shares and Total Voting RightsExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
finance.yahoo.com - September 21 at 7:59 AM
AMPE Says Ampion Improves COVID-19 Symptoms, AMYT At Ease, ITCI Impresses With Depression Trial DataAMPE Says Ampion Improves COVID-19 Symptoms, AMYT At Ease, ITCI Impresses With Depression Trial Data
nasdaq.com - September 10 at 7:28 AM
POSITIVE TOP LINE RESULTS FROM PHASE 3 TRIAL IN EBPOSITIVE TOP LINE RESULTS FROM PHASE 3 TRIAL IN EB
finance.yahoo.com - September 9 at 9:03 AM
AMRYT ANNOUNCES Q2 2020 RESULTS AND ISSUES POSITIVE REVENUE GUIDANCE FOR FY 2020AMRYT ANNOUNCES Q2 2020 RESULTS AND ISSUES POSITIVE REVENUE GUIDANCE FOR FY 2020
finance.yahoo.com - August 6 at 8:25 AM
AMRYT TO HOST KEY OPINION LEADER CALL ON EPIDERMOLYSIS BULLOSA DISEASE LANDSCAPEAMRYT TO HOST KEY OPINION LEADER CALL ON EPIDERMOLYSIS BULLOSA DISEASE LANDSCAPE
finance.yahoo.com - July 29 at 9:18 AM
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.